Philip J Tofilon
Overview
Explore the profile of Philip J Tofilon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
2624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Degorre C, Lohard S, Bobrek C, Rawal K, Kuhn S, Tofilon P
Sci Rep
. 2024 Jul;
14(1):17316.
PMID: 39068290
PRMT5 is a widely expressed arginine methyltransferase that regulates processes involved in tumor cell proliferation and survival. In the study described here, we investigated whether PRMT5 provides a target for...
2.
Yun H, Kramp T, Palanichamy K, Tofilon P, Camphausen K
Sci Rep
. 2024 May;
14(1):12363.
PMID: 38811596
Radiotherapy is the standard treatment for glioblastoma (GBM), but the overall survival rate for radiotherapy treated GBM patients is poor. The use of adjuvant and concomitant temozolomide (TMZ) improves the...
3.
Degorre C, Sutton I, Lehman S, Shankavaram U, Camphausen K, Tofilon P
Cancer Cell Int
. 2022 Dec;
22(1):389.
PMID: 36482431
Background: The invasive nature of GBM combined with the diversity of brain microenvironments creates the potential for a topographic heterogeneity in GBM radioresponse. Investigating the mechanisms responsible for a microenvironment-induced...
4.
Lehman S, Wechsler T, Schwartz K, Brown L, Porco J, Devine W, et al.
Mol Cancer Ther
. 2022 Jun;
21(9):1406-1414.
PMID: 35732578
A fundamental component of cellular radioresponse is the translational control of gene expression. Because a critical regulator of translational control is the eukaryotic translation initiation factor 4F (eIF4F) cap binding...
5.
Lehman S, Schwartz K, Maheshwari S, Camphausen K, Tofilon P
Sci Rep
. 2022 Mar;
12(1):4059.
PMID: 35260696
Increased ribosome biogenesis is a distinguishing feature of cancer cells, and small molecule inhibitors of ribosome biogenesis are currently in clinical trials as single agent therapy. It has been previously...
6.
Lehman S, Wilson E, Camphausen K, Tofilon P
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34639005
Towards improving the efficacy of radiotherapy, one approach is to target the molecules and processes mediating cellular radioresponse. Along these lines, translational control of gene expression has been established as...
7.
Yun H, Lee J, Kil W, Kramp T, Tofilon P, Camphausen K
Mol Cancer Ther
. 2021 Jun;
20(9):1672-1679.
PMID: 34158343
AZD0530, a potent small-molecule inhibitor of the Src kinase family, is an anticancer drug used in the treatment of various cancers. In the case of glioblastoma (GBM), where resistance to...
8.
McAbee J, Degorre-Kerbaul C, Tofilon P
Methods Mol Biol
. 2021 Mar;
2269:37-47.
PMID: 33687670
Ionizing radiation is a critical component of glioblastoma (GBM) therapy. Recent data have implicated glioblastoma stem-like cells (GSCs) as determinants of GBM development, maintenance, and treatment response. Understanding the response...
9.
Lee J, Ayat N, Sun Z, Tofilon P, Lu Z, Camphausen K
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33158243
Radiation therapy is a mainstay in the standard of care for glioblastoma (GBM), thus inhibiting the DNA damage response (DDR) is a major strategy to improve radiation response and therapeutic...
10.
McAbee J, Degorre-Kerbaul C, Valdez K, Wendler A, Shankavaram U, Watts C, et al.
J Neurooncol
. 2020 Oct;
149(3):383-390.
PMID: 33057920
Purpose: Glioblastoma (GBM) is characterized by extensive clonal diversity suggesting the presence of tumor cells with varying degrees of treatment sensitivity. Radiotherapy is an integral part of glioblastoma treatment. Whether...